

II. Financial highlights (more detail will be available in Page 4 and onward)

Sales and earnings (Billions of Yen)	FY05	FY06	FY07	FY08	Estimate FY2009	FY2008 1-2Q Total	FY2009 1-2Q Total	vs. FY2008 1-2Q Total	increase/ decrease
Net Sales	1,212.2	1,305.2	1,374.8	1,538.3	1,480.0	807.1	755.5	-51.7	-6.4%
Operating Income	402.8	458.5	423.1	306.5	395.0	85.0	242.5	157.5	185.2%
<% of net sales>	<33.2%>	<35.1%>	<30.8%>	<19.9%>	<26.7%>	<10.5%>	<32.1%>	<21.6pt>	
Ordinary Income	485.4	585.0	536.4	327.2	400.0	101.0	254.9	153.9	152.4%
<% of net sales>	<40.0%>	<44.8%>	<39.0%>	<21.3%>	<27.0%>	<12.5%>	<33.7%>	<21.2pt>	
Net Income	313.2	335.8	355.5	234.4	280.0	71.8	189.6	117.8	164.2%
<% of net sales>	<25.8%>	<25.7%>	<25.9%>	<15.2%>	<18.9%>	<8.9%>	<25.1%>	<16.2pt>	
R&D Expenses	169.6	193.3	275.8	453.0	310.0	321.1	135.6	-185.5	-57.8%
<% of net sales>	<14.0%>	<14.8%>	<20.1%>	<29.5%>	<20.9%>	<39.8%>	<17.9%>	<-21.8pt>	
Equity in earnings of unconsolidated subsidiaries and affiliates	54.2	66.2	56.7	2.9		2.5	0.6	-2.0	-77.4%
Overseas Sales	537.1	643.5	694.2	843.1	770.0	456.4	408.3	-48.1	-10.5%
<% of net sales>	<44.3%>	<49.3%>	<50.5%>	<54.8%>	<52.0%>	<56.5%>	<54.0%>	<-2.5pt>	
Net Sales of Ethical drugs segment	1,019.1	1,144.1	1,210.2	1,384.1	1,330.0	726.4	680.7	-45.7	-6.3%
Ethical drugs Sales* (Consolidated basis)	894.6	1,010.4	1,079.8	1,253.9		659.3	616.7	-42.6	-6.5%

*Excluding sales of products for which Takeda acts as a distributor to wholesalers

Sales and earnings by business segment (Billions of Yen)	FY05	FY06	FY07	FY08	FY2008 1-2Q Total	FY2009 1-2Q Total	vs. FY2008 1-2Q Total	increase/ decrease
Net Sales	1,212.2	1,305.2	1,374.8	1,538.3	807.1	755.5	-51.7	-6.4%
Pharmaceutical segment	1,074.5	1,202.8	1,272.1	1,448.5	760.3	713.1	-47.3	-6.2%
Ethical drugs	1,019.1	1,144.1	1,210.2	1,384.1	726.4	680.7	-45.7	-6.3%
Japan	493.5	514.9	529.7	549.0	274.4	276.1	1.7	0.6%
Overseas	525.6	629.1	680.6	835.1	452.0	404.6	-47.5	-10.5%
Consumer Healthcare	55.4	58.7	61.8	64.4	33.9	32.4	-1.5	-4.5%
Others	137.7	102.4	102.7	89.9	46.8	42.4	-4.4	-9.4%
Operating Income	402.8	458.5	423.1	306.5	85.0	242.5	157.5	185.2%
Pharmaceutical segment	388.1	448.2	411.3	296.9	80.1	240.0	159.9	199.7%
Others	14.7	10.2	11.7	9.5	4.9	2.5	-2.4	-49.2%

Sales and earnings by geographical segment (Billions of Yen)	FY05	FY06	FY07	FY08	FY2008 1-2Q Total	FY2009 1-2Q Total	vs. FY2008 1-2Q Total	increase/ decrease
Net sales	1,212.2	1,305.2	1,374.8	1,538.3	807.1	755.5	-51.7	-6.4%
Japan	873.0	854.6	859.3	826.6	425.7	398.3	-27.4	-6.4%
Americas	214.2	307.8	357.9	571.7	302.6	289.4	-13.1	-4.3%
Europe	116.7	132.5	147.3	131.0	74.1	62.6	-11.4	-15.5%
Asia	8.3	10.3	10.3	9.1	4.8	5.1	0.3	5.9%
Operating Income	402.8	458.5	423.1	306.5	85.0	242.5	157.5	185.2%
Japan	517.3	530.4	540.1	520.4	272.8	257.6	-15.2	-5.6%
Americas	32.6	89.4	125.7	187.4	104.7	107.3	2.6	2.5%
Europe	24.6	32.7	32.0	31.9	19.4	16.5	-2.9	-15.1%
Asia	1.6	2.0	1.8	1.4	0.8	0.7	-0.1	-8.0%
Eliminations/Corporate	-173.3	-196.0	-276.5	-434.5	-312.6	-139.6	173.1	

Balance sheets (Billions of Yen)	FY05	FY06	FY07	FY08	FY2008 2Q End	FY2009 2Q End	vs. FY08
Current Assets	2,372.0	2,357.7	2,243.8	1,475.6	1,548.0	1,506.0	30.4
Tangible fixed assets	215.7	238.4	236.1	258.5	253.9	264.9	6.4
Intangible fixed assets	5.3	10.8	10.2	747.7	843.1	658.1	-89.6
Investment and other assets	449.3	465.6	359.2	278.4	334.0	310.9	32.6
Total assets	3,042.3	3,072.5	2,849.3	2,760.2	2,979.1	2,739.9	-20.3
Current liabilities	488.2	442.4	428.7	472.1	496.6	429.9	-42.2
Long-term liabilities	158.4	169.0	98.0	234.2	291.3	221.2	-13.0
Total Liabilities	646.7	611.4	526.7	706.3	787.9	651.1	-55.2
Minority interests	47.2	-	-	-	-	-	-
Shareholders' equity	2,348.4	-	-	-	-	-	-
Net Assets	-	2,461.1	2,322.5	2,053.8	2,191.2	2,088.8	35.0
Shareholders' equity	-	2,216.7	2,314.2	2,124.4	2,155.8	2,241.5	117.1
Adjustments for valuation, foreign currency translation and others	-	203.6	-33.4	-113.0	-7.1	-195.8	-82.8
Minority interests	-	40.9	41.7	42.4	42.5	43.1	0.7
Shareholder's Equity Ratio (%)	77.2%	78.8%	80.0%	72.9%	72.1%	74.7%	1.8pt
Treasury Stock	3.0	193.9	322.6	1.1	1.3	1.0	-0.1

ROE•EPS•Dividend(Yen)	FY05	FY06	FY07	FY08	Estimate FY2009	FY2008 1-2Q Total	FY2009 1-2Q Total
ROE (Return on equity)	14.4%	14.1%	15.1%	10.9%	13.7%	6.5%	17.3%
EPS (Earnings per share)	353.47	386.00	418.97	289.82	354.72	87.33	240.24
Pro Forma EPS (Earnings per share) *	332.33	356.96	391.48	470.30	424.39	234.30	278.79
Annual dividends per share	106.00	128.00	168.00	180.00	180.00	88.00	90.00
Payout ratio	30.0%	33.2%	40.1%	62.1%	50.7%	100.8%	37.5%
Payout ratio for Pro-Forma Earnings **	30.0%	33.2%	40.1%	38.3%	44.2%	35.8%	33.7%

* Excluding extraordinary gains and losses and extraordinary factors related to corporate acquisitions and others.

** On earnings before amortization of intangible assets associated with acquisition of MILLENNIUM as a wholly owned subsidiary.

Shares	FY05	FY06	FY07	FY08	FY2008 2Q End	FY2009 2Q End
Number of shares outstanding (1,000)	889,272	889,272	889,272	789,666	815,152	789,666
(Treasury Stock (1,000))	(4,073)	(29,895)	(46,411)	(303)	(297)	(284)
Stock price at year-end (Yen)	6,710	7,730	4,990	3,400	5,250	3,740
Total market value (Billions of Yen)	5,967.0	6,874.1	4,437.5	2,684.9	4,279.6	2,953.4

Number of employees (*)	FY05	FY06	FY07	FY08	FY2008 2Q End	FY2009 2Q End	vs. FY08
Consolidated	15,069	14,993	15,487	19,362	19,210	19,769	407
(Unconsolidated)	(5,834)	(5,653)	(5,798)	(6,124)	(6,184)	(6,435)	(311)

(*) Employees working in Takeda Pharmaceutical Company Limited and its consolidated subsidiaries

Exchange rate(Yen)	FY05	FY06	FY07	FY08	FY2008 1-2Q	FY2009 1-2Q	Estimate FY2009 3-4Q
US\$ Average (Apr.-Mar.)	113	117	114	101	106	95	90
Euro Average (Apr.-Mar.)	138	150	162	143	163	133	135